to reduce the risk of kidney disease worsening, kidney failure (end-stage kidney disease), and death due to cardiovascular disease in adults with type 2 diabetes and chronic kidney disease
Recent technology, such as nanomedicine, further enhances tripeptide effects in many therapies
IGF-1 LR3 has been extensively used in muscle satellite cell research, bone biology, neuroprotection models, and metabolic signaling studies as a surrogate for sustained IGF-1 receptor activation
Current FDA indications and many insurance policies generally reflect those populations
Phytochem 77:1645
Thats just a drug company strategy for getting a broader indication for these medications rebranding them and marketing them for weight loss. The cost of a GLP-1 medication may be intimidating in that one needs to remain on the drug long-term to maintain its effect for diabetes, weight loss, or perhaps a reduction in depression and anxiety